Evidence map›Paper›PMID 32762699›Full record

ArticleMicrobial cell factories2020

TAK-242 ameliorates DSS-induced colitis by regulating the gut microbiota and the JAK2/STAT3 signaling pathway.

Jiajia Wang, Guannan Zhu, Cheng Sun, Kangwei Xiong, Tingting Yao, Yuan Su, Haiming Fang

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Physical exercise and inflammation in Parkinson's disease: a review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. LRRK2NPJ Parkinson's disease · 2026
    Article
  9. Article
  10. Frontiers in microbiology · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiajia WangDepartment of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China. wjj@ahmu.edu.cn.
Guannan ZhuDepartment of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
Cheng SunDepartment of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
Kangwei XiongDepartment of Gastroenterology and Hepatology, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.
Tingting YaoDepartment of Gastroenterology and Hepatology, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.
Yuan SuDepartment of Gastroenterology and Hepatology, The Second Hospital of Anhui Medical University, Hefei, Anhui, China.
Haiming FangDepartment of Gastroenterology and Hepatology, The Second Hospital of Anhui Medical University, Hefei, Anhui, China. haimingfang@ahmu.edu.cn.ORCID http://orcid.org/0000-0001-7436-7858
Anhui Medical University · CN

Funding

the Anhui Natural Science Foundation NO.1408085MH178the University Natural Science Research Project of Anhui Province NO. KJ2016A342
6 · The paper itself

Abstract

backgroundThe goal of the present study was to investigate the effects of TAK-242 on the gut microbiota and the TLR4/JAK2/STAT3 signaling pathway in mice with dextran sulfate sodium (DSS)-induced colitis.

resultsAt the phylum level, Bacteroidetes, Firmicutes, Actinobacteria, Cyanobacteria, Epsilonbacteraeota and Proteobacteria were the primary microbiota in the five groups. TAK-242 treatment significantly enhanced Verrucomicrobia and Actinobacteria; significantly decreased Cyanobacteria, Epsilonbacteraeota and Proteobacteria; and particularly promoted the growth of Akkermansia. TAK-242 markedly alleviated DSS-induced colitis symptoms and colonic lesions by promoting IL-10 release, inhibiting IL-17 release, downregulating TLR4 and JAK2/STAT3 mRNA and protein expression and increasing JAK2/STAT3 phosphorylation.

conclusionTAK-242 modulates the structure of the gut microbiota in colitis and may be a novel therapeutic candidate for ulcerative colitis.

Indexed as

AnimalsBacteriaColitisColonCytokinesDextran SulfateFecesGastrointestinal MicrobiomeJanus Kinase 2MaleMiceMice, Inbred C57BLSignal TransductionSTAT3 Transcription FactorSulfonamidesToll-Like Receptor 4CytokinesDextran Sulfateethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylateJak2 protein, mouseJanus Kinase 2Stat3 protein, mouseSTAT3 Transcription FactorSulfonamidesTlr4 protein, mouseToll-Like Receptor 4Gut microbiotaInflammatory bowel diseaseJAK/STAT signaling pathwayTAK-242TLR-4Ulcerative colitis

Identifiers

PMID32762699
PMCPMC7412642
OpenAlexW3047454819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.